These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Problems in the management of cytomegalovirus infection in patients with AIDS. Connolly GM; Nelson MR; Barton SE; Gazzard BG Int J STD AIDS; 1991; 2(6):405-10. PubMed ID: 1664242 [No Abstract] [Full Text] [Related]
29. [Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient]. Nicoli F; Dhiver C; Chave B; Poizot-Martin I; Gastaut JA; Gastaut JL Presse Med; 1992 Mar; 21(9):436. PubMed ID: 1314379 [No Abstract] [Full Text] [Related]
30. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Hardy WD Am J Med; 1992 Feb; 92(2A):30S-35S. PubMed ID: 1531285 [TBL] [Abstract][Full Text] [Related]
31. Didanosine and foscarnet marketed for use by patients with AIDS. Clin Pharm; 1992 Jan; 11(1):4, 6. PubMed ID: 1309689 [No Abstract] [Full Text] [Related]
33. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Chrisp P; Clissold SP Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982 [TBL] [Abstract][Full Text] [Related]
34. Foscarnet infusion at home. Wood G; Whitby M; Hogan P; Frazer I Lancet; 1989 Jan; 1(8630):156. PubMed ID: 2563066 [No Abstract] [Full Text] [Related]
35. The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. Barditch-Crovo PA; Petty BG; Gambertoglio J; Nerhood LJ; Kuwahara S; Hafner R; Lietman PS; Kornhauser DM Antiviral Res; 1998 Jun; 38(3):209-12. PubMed ID: 9754889 [TBL] [Abstract][Full Text] [Related]
36. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590 [TBL] [Abstract][Full Text] [Related]
37. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971 [TBL] [Abstract][Full Text] [Related]
38. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. Jacobson MA; O'Donnell JJ J Acquir Immune Defic Syndr (1988); 1991; 4 Suppl 1():S11-5. PubMed ID: 1848616 [TBL] [Abstract][Full Text] [Related]
39. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. Farthing C; Anderson MG; Ellis ME; Gazzard BG; Chanas AC J Med Virol; 1987 Jun; 22(2):157-62. PubMed ID: 3039052 [TBL] [Abstract][Full Text] [Related]
40. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. Katlama C; Dohin E; Caumes E; Cochereau-Massin I; Brancon C; Robinet M; Rogeaux O; Dahan R; Gentilini M J Acquir Immune Defic Syndr (1988); 1992; 5 Suppl 1():S18-24. PubMed ID: 1318363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]